Havana.- The Cuban company CIMAB S.A., which commercializes the products of the Molecular Immunology Center, increased exports in 2003.
Company executives pointed out that new markets were explored last year, and production capacity was increased due to the introduction of state-of-the-art technology.
CIMAB S.A. has several joint ventures, including one in China and another in India.
The firm’s offers include the granulocytic colonies stimulating factor, erythropoietin, interferon, monoclonal antibodies and recombinant proteins, among others.
CIMAB S.A. also produces monoclonal drugs used to mitigate rejection of transplanted organs, mainly kidneys.
The latter is an immune suppressant that is commercialized in over a dozen countries, including Mexico, Argentina, Uruguay, El Salvador, India, China and Russia.